# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN-TD
- Date: 1917-08-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season ahead. **S**

## History of present illness

Madam Walker returns ten weeks after her preventive visit; the laboratory day was booked before her summer trips, as planned. Her home readings average 123/77 on losartan 100 mg, amlodipine 5 mg and empagliflozin 10 mg. She has had no ankle swelling, dizziness, genital itching or muscle aches. Her mammogram was normal and her HPV test and stool test were negative. Having read about APOL1 testing, she has decided not to have it for now, since it would not change her treatment; she knows it remains available. She plans an autumn of travel and asked what she should watch for on the road. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 123/77 |
| Screening | Mammogram normal; HPV and stool tests negative |
| APOL1 testing | Declined for now, her choice |
| Mood | PHQ-9 3 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness; weight down 3.2 kg since intake |
| Cardiovascular | Negative | No ankle swelling or palpitations |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Negative | No muscle aches |
| Psychiatric | Negative | Mood steady |

5 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet each morning **S**
- Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 75.8 kg; BMI 28.5 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.8 mmol/L; Bicarbonate (total CO2): 25 mmol/L; Creatinine: 1.3 mg/dL (high); eGFR (CKD-EPI 1912, race-free): 50 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 128 mg/g (high); Hemoglobin: 12.6 g/dL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Bicarbonate (total CO2): 25 mmol/L at baseline, 25 mmol/L at this visit **S**
- Creatinine: 1.22 mg/dL (high) at baseline, 1.3 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 1912, race-free): 54 mL/min/1.73 m² (low) at baseline, 50 mL/min/1.73 m² (low) at this visit **S**
- Urine albumin-to-creatinine ratio: 286 mg/g (high) at baseline, 128 mg/g (high) at this visit **S**
- Hemoglobin: 12.4 g/dL at baseline, 12.6 g/dL at this visit **S**
- PHQ-9: 4 at baseline, 3 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 72; weight 75.8 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Respiratory | Clear |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension with chronic kidney disease** (I12.9). At goal: 122/76 in the clinic, 123/77 at home, on three medicines without side effects. **S**
   - Continue losartan 100 mg, amlodipine 5 mg and home readings twice a week on the road.
2. **Chronic kidney disease G3a A2** (N18.31). Urine albumin-to-creatinine ratio 128 mg/g, 56% below baseline but still moderately increased. Potassium 4.8 mmol/L; creatinine 1.30 mg/dL, eGFR 50 (race-free CKD-EPI 1912), stable on treatment. Hemoglobin 12.6 g/dL. 5-year kidney failure risk 1.7%. **S**
   - Continue losartan and empagliflozin.
   - Urine albumin, kidney function and potassium every six months; calcium, phosphate and parathyroid hormone at one year.
   - Video review with Dr. Achterberg next month, as he planned.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 122/76 |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Average 123/77 |
| Examination | Weight and BMI | Every visit | Completed today | 75.8 kg, down 3.2 kg since intake |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 1912, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Completed today | Potassium 4.8, bicarbonate 25 mmol/L; creatinine 1.30 mg/dL, eGFR 50 |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Completed today | 128 mg/g, 56% lower than baseline |
| Laboratory | Hemoglobin | Yearly in CKD G3 | Completed today | 12.6 g/dL |
| Laboratory | Calcium, phosphate and parathyroid hormone | At diagnosis of G3a, then every 6 to 12 months | Due | Normal at diagnosis; repeat at one year |
| Survey | Kidney failure risk equation (4-variable), 2- and 5-year | Yearly for G3 to G5 | Completed today | 5-year risk 1.7% |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 98 mg/dL in April; yearly panel at one year |
| Examination | Fundus examination | Yearly | Due | Dilated examination by an optometrist booked for the autumn |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | No ankle swelling, dizziness, genital itching or muscle aches; sick-day card current |
| Medication safety | Vaccination review | Yearly in CKD | Completed today | Hepatitis B dose 2 given today; influenza and COVID-19 due in the autumn; zoster from 50 |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Salt-free seasoning at home; restaurant choices on the road |
| Survey | Depression screen (PHQ-9) | At intake, then yearly | Completed today | PHQ-9 3 |
| Referral | Nephrology review | At diagnosis; then about six months, by video if she prefers | Due | Video review with Dr. Achterberg booked for next month |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated. Outcome by 1917-08-17: 122/76 in the clinic; home average 123/77 on losartan 100 mg and amlodipine 5 mg. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. Outcome by 1917-08-17: 286 to 294 mg/g at baseline; 128 mg/g at six months, 56% lower. **S**
- Kidney function stable, without a fall in eGFR of more than 30% after starting treatment. Outcome by 1917-08-17: eGFR 54 to 55 at baseline; 50 to 51 on treatment, a dip of under 10%. **S**
- Sodium under 2 g a day using foods she likes, at home and on the road. Outcome by 1917-08-17: Salt-free seasoning at home and ordering strategies on the road; restaurant meals still the hardest part. **S**
- LDL cholesterol lower by at least 30%. Outcome by 1917-04-27: 174 to 98 mg/dL on atorvastatin 20 mg, 44% lower. **S**
- Care that fits her work: every check scheduled around her travel, by her choice. Outcome by 1917-08-17: Laboratory checks booked before trips are planned after two missed checks; video visits between trips. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American College of Cardiology and American Heart Association (Circulation 2019)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Video review with nephrology next month. Influenza and COVID-19 vaccines in the autumn; zoster after her birthday. Review in six months with urine albumin, kidney function, the yearly lipid panel and calcium, phosphate and parathyroid hormone, booked on a home day. Hold losartan and empagliflozin on days of vomiting, diarrhea or not eating. **S**

